DESLORATADINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H19ClN2
Molecular Weight	310.8212
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

c1cc2CCc3cc(ccc3C(=C4CCNCC4)c2nc1)Cl

InChI

InChIKey=JAUOIFJMECXRGI-UHFFFAOYSA-N

InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2

HIDE SMILES / InChI

Molecular Formula	C19H19ClN2
Molecular Weight	310.8212
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11243504
Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 300 Target ID: CHEMBL231 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Antagonist 2575		0.87 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Seasonal allergic rhinitis 61 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 7968	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 1.00889277E12
Perennial allergic rhinitis 45 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 7968	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 1.00889277E12
Chronic idiopathic urticaria 10 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 7968	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 1.00889277E12

C_max

Value	Dose	Co-administered	Analyte	Population
4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
56.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
27 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
84.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	Disc. AE: Somnolence, Abdominal pain... AEs leading to discontinuation/dose reduction: Somnolence (1 patient) Abdominal pain (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25
45 mg 1 times / day multiple, oral Highest studied dose Dose: 45 mg, 1 times / day Route: oral Route: multiple Dose: 45 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf

AEs

AE	Significance	Dose	Population
Abdominal pain	1 patient Disc. AE	1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25
Somnolence	1 patient Disc. AE	1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1469	inhibitor 1318	substrate 1038 inhibitor 1421	inhibitor 1359

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1268 CYP2C8 761 CYP2C19 1215 CYP2B6 679 CYP3A4/5 225 UGT1A1 174 UGT1A3 76 UGT1A4 67 UGT1A6 94 UGT1A9 102 UGT2B7 130 UGT2B10 24 UGT2B15 56 UGT2B17 13 UGT1A7 17 UGT1A8 29 UGT1A10 26 UGT2B4 20 P-gp 1087	CYP1A2 892 CYP2B6 575 CYP1A1 302 CYP2C19 830 UGT2B10 111 P-gp 1222

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1406	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C19 1277	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C8 810	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C9 1362	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
UGT1A1 219	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A3 82	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A4 70	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A6 126	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A7 19	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A8 41	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A9 107	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT2B15 56	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT2B7 138	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
P-gp 1253	inhibitor 2612 Sources: https://pubmed.ncbi.nlm.nih.gov/11454724/	not significant [IC50 43 uM]
UGT2B10 26	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	strong [Ki 1.3 uM]
CYP2B6 845	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
CYP2D6 1455	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
CYP3A4/5 277	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
UGT1A10 35	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]
UGT2B17 15	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]
UGT2B4 20	inhibitor 2612 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A1 302	substrate 2751 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0	likely
CYP1A2 892	substrate 2751 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely
CYP2B6 575	substrate 2751 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely
CYP2C19 830	substrate 2751 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0	likely	no (pharmacogenomic study) Comment: pharmacogenotype 2C19 does not correlate with systemic exposure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0
CYP2D6 1038	substrate 2751 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely	no (pharmacogenomic study) Comment: lack of correlation in between 2D6 genotype and 3-OH DCL formation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0
CYP3A4 1469	substrate 2751 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=33 Page: 10.0	likely	weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=33 Page: 10.0
UGT2B10 111	substrate 2751 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 1.0	yes
P-gp 1222	substrate 2751 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388404/	yes	weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388404/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1391	inhibitor 1373 Sources: https://pubmed.ncbi.nlm.nih.gov/11243504/#:~:text=Preclinical%20studies%20also%20show%20that,in%20preclinical%20and%20clinical%20studies.

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:291342	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:291342
ChemicalBook	CB3462564	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3462564
MolPort	MolPort-000-883-875	https://www.molport.com/shop/molecule-link/MolPort-000-883-875
Selleck Chemicals	desloratadine	http://www.selleckchem.com/products/desloratadine.html
ZINC	ZINC000000001261	http://zinc15.docking.org/substances/ZINC000000001261
eMolecules	877481	https://www.emolecules.com/cgi-bin/more?vid=877481

PubMed

Title	Date	PubMed
Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice.	2000 Apr 29	10784544
[The effect of second generation histamine antagonists on the heart].	2001	11575008
Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction.	2001	11243503
Desloratadine in the treatment of chronic idiopathic urticaria.	2001	11243502
Desloratadine activity in concurrent seasonal allergic rhinitis and asthma.	2001	11243501
Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis.	2001	11243500
Applications of new liquid chromatography-tandem mass spectrometry technologies for drug development support.	2001 Aug 10	11554418
[Urticaria. Finally undisturbed sleep].	2001 Jul 26	11524992
Chronic idiopathic urticaria treatment.	2001 Jul-Aug	11674926
Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.	2001 Mar	11318079
Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.	2001 Mar	11240972
In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.	2001 Sep	11502723
Mediator antagonists in the treatment of allergic disease.	2001 Sep-Oct	11715214
Second-generation antihistamines in asthma therapy: is there a protective effect?	2002	14720073
Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion.	2002	14720057
Advances in allergy management.	2002	12492727
Impact and modulation of nasal obstruction.	2002	12492726
Investigation of an enhanced resolution triple quadrupole mass spectrometer for high-throughput liquid chromatography/tandem mass spectrometry assays.	2002	12391581
A pharmacokinetic profile of desloratadine in healthy adults, including elderly.	2002	12169042
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.	2002	11978146
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139].	2002 Aug 5	12162793
Treatment of allergic rhinitis.	2002 Dec 16	12517578
Are antihistamines useful in managing asthma?	2002 Feb	11964751
Desloratadine (Clarinex).	2002 Mar 18	11941265
Gateways to clinical trials.	2002 May	12092009
Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion.	2002 Nov	12452207
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis.	2002 Oct	12372132
Severe hepatotoxicity after application of desloratadine and fluconazole.	2003	12975558
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.	2003 Apr	12740532
Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men.	2003 Aug	14512130
Gateways to clinical trials.	2003 Dec	14735233
Interactions of olopatadine and selected antihistamines with model and natural membranes.	2003 Dec	14704897
Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma.	2003 Feb	12589354
The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study.	2003 Jan 6	12515585
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma.	2003 Jul	12847492
Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis.	2003 Mar	12642846
[Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis].	2003 May 25	12847854
Desloratadine for allergic rhinitis.	2003 Nov 15	14655812
A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis.	2003 Oct	14582817
Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment.	2003 Oct	14530791
Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma.	2003 Oct 25	14552827
[Modern antihistaminics against allergic rhinitis. Better breathing without side effects].	2003 Oct 30	14655512
Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine.	2004 Apr	15005765
Inhibition of cold urticaria by desloratadine.	2004 Jan	14754651
Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research.	2004 Jan	14741075
Gateways to clinical trials.	2004 Jan-Feb	14988742
High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs.	2004 Mar 10	15019035

Patents

Sample Use Guides

In Vivo Use Guide

Adults and Adolescents 12 Years of Age and Over: take 5 mg tablet once daily. Children 6 to Years of Age: take 2.5 mg tablet once daily. Children 12 Months to 5 Years of Age: take 1.25 mg tablet once daily. Children 6 to 11 Months of Age: 1 mg tablet once daily.

Route of Administration: Oral

In Vitro Use Guide

Nasal epithelial cells (activated by 1 uM of histamine) were treated with 10 uM of desloratadine and the inhibitory activity of the drug on expression of ICAM-1 and HLA-DR was studied.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:08:37 UTC 2021` Edited by `admin` on `Fri Jun 25 21:08:37 UTC 2021`
Record UNII	FVF865388R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DESLORATADINE

Official Name

English

LORATADINE RELATED COMPOUND A [USP]

Common Name

English

8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDINYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2-BPYRIDINE

Common Name

English

DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, URTICARIA)

Brand Name

English

DESLORATADINE RATIOPHARM

Brand Name

English

8-CHLORO-6,11-DIHYDRO-11(4-PIPERIDYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2-B) PYRIDINE

Common Name

English

DENOSIN

Brand Name

English

DESLORATADINE [INN]

Common Name

English

DASSELTA

Brand Name

English

NSC-759824

Code

English

DESLORATADINE [MART.]

Common Name

English

RUPATADINE FUMARATE IMPURITY B [EP]

Common Name

English

NEOCLARITYN

Brand Name

English

DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)

Brand Name

English

DESLORATADINE [MI]

Common Name

English

DESLORATADINE [VANDF]

Common Name

English

DESLORATADINE [USP-RS]

Common Name

English

LORATADINE SPECIFIED IMPURITY D [EP]

Common Name

English

DESLORATADINE [USP MONOGRAPH]

Common Name

English

CLARINEX

Brand Name

English

DESCARBOETHOXYLORATADINE

Common Name

English

DESLORATADINE ACTAVIS

Brand Name

English

DESLORATADINE TEVA (AUTHORIZED: RHINITIS, URTICARIA)

Brand Name

English

DESLORATADINE [ORANGE BOOK]

Common Name

English

8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDINYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE

Common Name

English

CLARINEX-D COMPONENT DESLORATADINE

Common Name

English

DESLORATADINE [WHO-DD]

Common Name

English

OPULIS

Brand Name

English

SCH-34117

Code

English

AZOMYR

Brand Name

English

ALLEX

Brand Name

English

DESLORATADINE TEVA

Brand Name

English

AERIUS

Brand Name

English

DESLORATADINE [JAN]

Common Name

English

LORATADINE RELATED COMPOUND A [USP-RS]

Common Name

English

DESLORATADINE [EMA EPAR]

Common Name

English

DESLORATADINE [EP MONOGRAPH]

Common Name

English

DESLORATADINE [USAN]

Common Name

English

DESLORATADINE COMPONENT OF CLARINEX-D

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

DESLORATADINE TEVA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)